Notably, our results further uncovered the oncogenic activities of IL‐2 in prostate cancer cells, wherein IL‐2 was subjected to TRIM66‐positive regulation, and IL‐2 silencing greatly compromised cell proliferation, invasion and migration. The gene discussed is TRIM66; the disease is Familial prostate cancer.